Evidence map›Paper›PMID 25151961›Full record

ArticleOncogene2015

Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.

M H Lopes, T G Santos, B R Rodrigues, N Queiroz-Hazarbassanov, I W Cunha, A P Wasilewska-Sampaio, B Costa-Silva, F A Marchi, L F Bleggi-Torres, P I Sanematsu and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Humanization and Maturation of an Anti-PrPc Antibody.Bioengineering (Basel, Switzerland) · 2024
    Article
  6. Article
  7. Review
  8. Emerging roles of the cellular prion protein (PrPCellular and molecular life sciences : CMLS · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. High Expression ofCancers · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression.Journal of molecular medicine (Berlin, Germany) · 2021
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

M H Lopes1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil [3] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
T G Santos1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
B R Rodrigues1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
N Queiroz-Hazarbassanov1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
I W CunhaDepartment of Pathology, AC Camargo Cancer Center, São Paulo, Brazil.
A P Wasilewska-Sampaio1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
B Costa-Silva1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil.
F A Marchi1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil [3] Inter-institutional Grad Program on Bioinformatics, Institute of Mathematics and Statistics, USP-São Paulo University, São Paulo, Brazil.
L F Bleggi-Torres1] Department of Pathology, Federal University of Paraná, Curitiba, Brazil [2] Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.
P I SanematsuDepartment of Neurosurgery, AC Camargo Cancer Center, São Paulo, Brazil.
S H SuzukiDepartment of Neurosurgery, AC Camargo Cancer Center, São Paulo, Brazil.
S M Oba-ShinjoDepartment of Neurology, School of Medicine, University of São Paulo, Brazil.
S K N MarieDepartment of Neurology, School of Medicine, University of São Paulo, Brazil.
E ToulminDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.
A F HillDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia.
V R Martins1] International Research Center, AC Camargo Cancer Center, São Paulo, Brazil [2] National Institute for Translational Neuroscience and National Institute of Oncogenomics (CNPq/MCT/FAPESP), São Paulo, Brazil [3] Ludwig Institute for Cancer Research, São Paulo, Brazil.
AC Camargo Hospital · BRUniversidade de São Paulo · BRUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrP(C)) triggers a large number of trophic effects in the nervous system. We found that both PrP(C) and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrP(C) and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrP(C) binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrP(C) binding site (HOP230-245) abrogates this effect. PrP(C) knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrP(C)-HOP engagement is a promising approach for GBM therapy.

Indexed as

CognitionAmino Acid SequenceAnimalsCell Line, TumorCell ProliferationCognition DisordersFemaleGene Expression Regulation, NeoplasticGlioblastomaHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsHumansMaleMiceMolecular Sequence DataNeoplasm GradingHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsPeptide FragmentsPrions

Identifiers

PMID25151961
OpenAlexW2005280614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.